REVIEW article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1604448
This article is part of the Research TopicImaging to Guide Treatment in Brain TumorsView all 4 articles
The role of FET-PET in Patient Selection and Response Assessment for Reirradiation in Recurrent Glioblastoma
Provisionally accepted
- 1Department of Radiotherapy, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Pomeranian, Poland
- 2Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland, Bydgoszcz, Poland
- 3Faculty of Medical Sciences, Bydgoszcz University of Science and Technology, Bydgoszcz, Pomeranian, Poland
- 4Department of Clinical Oncology, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Pomeranian, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Radiation treatment with modern techniques is frequently used in the complex interdisciplinary management of glioblastoma, both in primary and recurrent setting. However, standard imaging limits the ability to precisely distinguish treatment-related changes from tumor progression and to accurately assess the outcomes of radiotherapy. Given the challenges, there is growing need for advanced imaging modalities that can enhance diagnostic precision and guide therapeutic decision. One such modality is FET-PET, whose role in glioblastoma radiotherapy is increasingly recognized -from target definition to response assessment and differentiation between progression and post-irradiation changes. Recently, PET RANO criteria have been published, providing an optimal strategy for evaluating treatment response using amino-acid PET. Earlier, contributions from the PET/RANO group also supported the integration of PET imaging in radiotherapy planning and monitoring of glioma patients. Increasing evidence highlights the advantages of amino-acid PET over standard RANO MRI in predicting overall survival. However, its value in case of patient selection and monitoring of reirradiation is less clear.In this narrative review, we aimed to summarize the published data on FET-PET in patients after initial treatment from the perspective of radiation oncologist. We focused on the role of FET-PET in accurate diagnosis of recurrence and in treatment response after reirradiation.
Keywords: Glioblastoma, Amino acid PET, Post-treatment changes, tumor progression, response assessment
Received: 01 Apr 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Zarębska, Blok, Marjański and Harat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Izabela Zarębska, Department of Radiotherapy, Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, 85-796, Pomeranian, Poland
Maciej Harat, Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland, Bydgoszcz, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.